Perfect Balance Health
- Peptide Therapy
- Erectile Dysfunction (ED) Treatment
- Hormone Replacement Therapy (HRT)
- Testosterone Replacement Therapy (TRT)
San Diego, CA
San Diego has the biotech corridor in Sorrento Valley and a strong military and endurance-athlete population, and peptide therapy has grown into a visible slice of the local wellness market. The clinics we track across La Jolla, Del Mar, Carmel Valley, and Hillcrest range from physician-led longevity practices to medspa-adjacent wellness offices offering sermorelin blends and growth hormone peptides. Most local prescribers have training or admitting privileges within the UC San Diego Health, Scripps, and Sharp network. The scene here skews toward clinics that serve Navy operators, masters athletes, and biotech professionals. The regulatory landscape shifted sharply in 2023 and 2024 when the FDA placed several widely prescribed peptides on its Category 2 bulk substances list, restricting which ingredients compounding pharmacies could legally source. That changed access overnight for BPC-157, CJC-1295, ipamorelin, and thymosin beta-4. Sermorelin and tesamorelin remain FDA-approved for specific indications, and reputable San Diego clinics now draw a clearer line between approved peptides and off-label research compounds than they did two years ago.
Regulatory context
Most research peptides used in regenerative medicine (BPC-157, TB-500, CJC-1295, ipamorelin) are not FDA-approved drugs. Sermorelin and tesamorelin hold FDA approvals for specific indications. In 2023 and 2024 the FDA placed several peptides into Category 2 on its Bulk Drug Substances Nominated for Use in Compounding list, which restricts 503A compounding pharmacies from sourcing those ingredients for patient-specific prescriptions. Section 503A covers traditional pharmacies; Section 503B covers FDA-registered outsourcing facilities operating under cGMP.
The California State Board of Pharmacy inspects sterile compounding facilities under stringent state rules that often exceed USP 797. The Board has issued citations for sourcing non-compliant bulk ingredients and for office-use stocking that should have flowed through a 503B. Non-resident pharmacies shipping into California must hold a current non-resident permit; the Board publishes disciplinary actions and annual inspection findings. Clinics dispensing from in-office stock of compounded peptides are examined closely.